Study Design. A retrospective cohort study. Objective. The aim of this study was to assess and compare the predictive accuracy of six models designed to estimate survival of patients suffering from spinal bone metastases Just (SBMs). Summary of Background Data. On the basis of the estimated survival of patients with SBM, extent of treatment can be adjusted. To aid clinicians in the difficult task of assessing probability of survival, prognostic scoring systems have been developed by Tomita, Tokuhashi, Van der Linden, Bauer, Rades, and Bollen. Methods. All patients who were treated for SBM between 2000 and 2010 were included in this international, multicenter, retrospective study (n ¼ 1379). Medical records were reviewed for all items needed to use the scoring systems. Survival time was calculated as the difference between start of treatment for SBM and date of death. Survival curves were estimated using the Kaplan-Meier method and accuracy was assessed with the c-statistic. Survival rates of the worst prognostic groups were evaluated at 4 months. Results. Median follow-up was 6.7 years [95% confidence interval (95% CI) 5.6-7.7] with a minimum of 2.3 years and a maximum of 12.3 years. The overall median survival was 5.1 months (95% CI 4.6-5.6). The most common primary tumors were breast (n ¼ 388, 28%), lung (n ¼ 318, 23%), and prostate cancer (n ¼ 259, 19%). The Tokuhashi, Bauer, Tomita, and Van der Linden models performed similar with a c-statistic of 0.64 to 0.66 and a 4-month accuracy of 62% to 65%. The Rades model (c-statistic 0.44) and Bollen model (c-statistic 0.70) had a 4-month accuracy of 69% and 75%, respectively. Conclusion. The Bollen model performs better than the other models. However, improvements are still warranted to increase the accuracy.
P rediction of survival has become an integral part of selecting the appropriate treatment for patients suffering from symptomatic spinal bone metastases (SBM). Depending on the symptoms, patients with a short expected survival are most likely to benefit from short radiotherapy regimens, best supportive care, or minimally invasive surgery. Patients with a relatively long expected survival will most likely benefit from high-dose radiotherapy or-in the case of radioresistant tumors and biomechanical instability-more extensive surgical interventions. Several studies have shown that the estimation of survival by clinicians in terminally ill patients is inaccurate and have suggested the use of prognostication models in order to prevent exposure of patients to unnecessarily extensive treatments. [1] [2] [3] Models [4] [5] [6] [7] [8] [9] [10] to aid in the decision-making process have been developed by Tokuhashi et al, 9 Bauer and Wedin 10 -later modified by Leithner et al 6 -Tomita et al, 5 Linden et al, 8 Rades et al, 4 and Bollen et al. 7 These models make use of a combination of different risk factors to estimate the survival of individual patients. Several smaller studies have been undertaken to assess the predictive value of some of the Patients were identified through database searches linking treatment and diagnostic codes and through database searches based on surgical coding. Information on date of death was obtained from medical records or by contacting the general practitioner or the civil registry office.
The primary data sources were the patient's clinical files, radiology reports, and admission forms. Baseline variables obtained before start of treatment were gender, age, primary tumor, location and number of SBM, the presence of visceral and/or brain metastases, the presence of extraspinal bone metastases, pretreatment functioning according to the Karnofsky performance status 14 (KPS), and neurological functioning according to the Frankel classification. 15 The Eastern Cooperative Oncology Group (ECOG) performance status 16 was obtained on the basis of the KPS values. Time to development of SBM was defined as the interval from primary cancer diagnosis to the diagnosis of SBM. 4 If required for a specific scoring system, primary tumors were classified as slow, moderate, or rapid growing. 5, 6, 11 All variables were further subdivided according to the instructions of each predictive model, resulting in different classifications for the same variable.
During the creation of the current database, visceral metastases were scored as either being present or not present. The models by Tomita et al 5 and Tokuhashi et al 9 further distinguish visceral metastases as either being removable or not removable. In our analysis, if visceral metastases were present, they were scored as ''not removable.'' Also, the model of Rades et al 4 scores the time to development of motor deficits. Retrospectively, this variable could not accurately be obtained from the medical records used to create this database. Therefore, the maximum number of points in the model was reduced from 25 to 21 and the minimum from 6 to 5. The cutoff scores for the predictive groups were changed accordingly. The model by Bollen et al 7 was created on the basis of a large percentage of patients also included in this study. Therefore, an additional analysis based on external data only was conducted for this model.
Statistical Analysis
Survival time was calculated as the time between the start of treatment for the spinal metastasis and the date of death or latest follow-up. Survival curves were estimated by using the Kaplan-Meier method and were compared using log-rank tests. Follow-up was assessed by employing the reverse Kaplan-Meier method. 17 Hazard ratios were estimated by using Cox proportional hazard models. All multivariate models were corrected for differences in survival between the participating centers. Harrell's c-statistic was used to assess the predictive power of each model. It estimates the probability of concordance between predicted and observed responses, with a value of 1.0 being perfect agreement. 18 For each model, survival rates of the predictive group with the lowest expected survival were assessed at 4 and 6 months. Survival rates of the predictive groups with the highest expected survival were assessed at 2 and 2 years. A P value of less than 0.05 was considered statistically significant. All analyses were performed using SPSS 20.0, Armonk, NY, IBM Corp. Ewing sarcoma
ACUP indicates adenocarcinoma of unknown primary; CI, confidence interval. Table 1 summarizes the characteristics of the 1379 patients studied. Fifty-two percent were male, and at baseline, the mean age was 64.6 AE 12.4 years. The SBMs were most commonly located in the thoracic part of the spine (n ¼ 376, 27%) and most patients had 3 or more SBM (n ¼ 730, 53%). Extraspinal bone metastases were found in 913 patients (66%) and visceral or brain metastases were found in 611 patients (44%). The majority of patients had no (n ¼ 746, 54%), or only minor (n ¼ 464, 34%) neurological deficit. Treatment consisted of radiotherapy in 1141 patients (83%) and 109 patients (8%) underwent a combination of surgery and radiotherapy. Thirty-three patients (2%) underwent only surgery and 96 patients (7%) had conservative treatment. The most prevalent primary tumors were breast cancer (n ¼ 388, 28%), lung cancer (n ¼ 318, 23%), prostate cancer (n ¼ 259, 19%), kidney cancer (n ¼ 90, 7%), and colon cancer (n ¼ 73, 5%). The remaining 18% consisted of 16 different primary tumors (Table 2) .
Time in Months
Median follow-up from start of treatment was 6.7 years [95% confidence interval (95% CI) 5.6-7.7], with a minimum of 2.3 years and a maximum of 12.3 years. Six patients moved abroad after treatment and were lost to follow-up. The overall median survival was 5.1 months (95% CI 4.6-5.6) (Figure 1 ). A total of 1318 patients (96%) died during the follow-up. Within 2 months after starting treatment, 379 patients (27%) died, whereas 257 patients (19%) survived for more than 2 years.
Multivariate analysis of each separate model showed that the primary tumor, performance status, the presence of visceral metastases, and the time to development of SBM were associated with survival. Neurological functioning or ambulatory status, the number of spinal bone metastases, and the number of extraspinal bone metastases were not significantly associated with survival in any of the models (Table 3 ). The median survival times and corresponding hazard ratios for each subgroup of all 6 models are summarized in Table 4 . Even though all the models are able to distinguish between short and long expected survival, the number of patients in each category differs greatly. Modelbased survival curves are shown in Figures 2A to F . Table 5 summarizes the c-statistic for each model, and the percentage of patients that were stratified correctly at 4, 6, 12, and 24 months. At 4 and 6 months, survival data from patients classified in the worst prognostic group of each model were used (eg, Tomita category ''Terminal'' or Bauer category ''Supportive care''), and at 12 and 24 months, survival data from patients classified in the best prognostic group of each model were used (eg, Tomita category ''Longterm'' or Bauer category ''Local control''). The models by Tokuhashi et al, 9 Bauer and Wedin, 10 and Tomita et al 5 have an identical c-statistic and a relatively low predictive ability, both for their worst and best prognostic groups. The model by Linden et al 8 has a similar c-statistic, but is much better at identifying patients with a longer survival. The model by Rades et al 4 has the lowest c-statistic, but shows relatively good predictive power for patients with short survival. However, patients with a long survival are poorly identified. The model by Bollen et al 7 has the highest c-statistic and is good at identifying patients with short survival and patients with long survival. When the results from the external data analysis are observed, the c-statistic remains almost identical. However, the number of patients stratified correctly at 4 months drops considerably.
DISCUSSION
In this multicenter, retrospective study of 1379 patients treated for symptomatic SBM, it is demonstrated how predictive models perform on a large independent dataset.
The most important limitation of this study is its retrospective design and the possibility of inaccurate interpretation of the source data. Also, the data were obtained from centers in 2 different European countries. Even though the quality of oncological care is considered to be excellent, differences in survival times between the centers were observed for some primary tumors, possibly resulting in lower predictive accuracy of the models. The multivariate analyses were adjusted for this center effect. One of the models was created by the same authors conducting the current study and was based on a large portion of patients also included in this study. This potential source of bias was addressed by conducting an extra analysis based on external data only.
The model by Rades et al 4 was adjusted due to the fact that information concerning time to development of motor deficits could not reliably be obtained. Considering that neurologic deficit or ambulatory status was not associated with survival, it is unlikely that omitting this variable had a large effect on our results. Also, resectability of visceral metastases could not be assessed and all visceral metastases were considered unresectable. The effect of this on the accuracy of the models by Tomita et al 5 and Tokuhashi et al 9 is unclear. In order to predict survival, the evaluated models utilize a total of 7 different variables. Each model has different guidelines on how to further categorize each variable, leading to different results for identical variables. As has been demonstrated, primary tumor, visceral metastases, and performance status are associated with survival, whereas the number of SBM and the presence of extraspinal bone metastases are not. On multivariate analysis, neurological functioning was also not associated with survival. Furthermore, patients presenting with neurologic deficit due to nerve root compression are difficult to classify using the Frankel classification, as it only pertains to neurologic deficit caused by spinal cord compression. We therefore suggest that neurological functioning and the duration of neurological deficit will be viewed as an indication for treatment, instead of a prognostic factor for estimating survival.
In 1990, Tokuhashi et al 19 created the first predictive model for SBM, and the 2005 revised version 9 is still one of the most commonly reported models to date. It was based on a retrospective analysis of 246 patients and uses 6 items to assign patients into 1 of 3 categories. In this study, 3 of these items were not associated with survival. The primary tumor classification was based on average survival periods for each cancer, but due to the low number of patients, this was not very accurate. Low scores for both the worst and best predictive groups make it difficult to justify the use of this model in a clinical setting.
The original model by Bauer and Wedin 10 was based on a retrospective analysis of 88 patients with spinal metastases and 153 patients with bone metastases in the extremities. Due to the fact that the presence of a pathologic fracture negatively influenced survival only in the extremities group, Leithner et al 6 modified the score for use in SBM. Even though it is one of the easiest models to use, the simple primary tumor classification and the lack of a performance score resulted in a low accuracy.
The model by Tomita et al 5 was based on a retrospective analysis of 67 patients and essentially consists of 4 items, as the ''bone metastases'' category includes both spinal and extraspinal metastases. The primary tumor classification in slow, moderate, and fast growing tumors has been shown to be quite accurate. Unfortunately, this model also lacks the incorporation of a performance score, resulting in a c-statistic identical to the models by Tokuhashi et al 9 and Bauer and Wedin. 10 The model by Linden et al 8 was based on 342 patients treated for painful SBM by means of radiotherapy within a multicenter, randomized, phase III trial. The model contained all 3 risk factors that were shown to be associated with survival in this article and has a c-statistic of 0.66. It performs better than the previous models, especially when identifying patients with a longer expected survival.
The model by Rades et al 4 was based on a retrospective analysis of 2029 patients, all of whom were treated with radiotherapy. With 7 items, it is the most elaborate score. The aim of this model was to identify patients with poor survival who may be candidates for best supportive care and it achieved this goal. In a clinical setting, however, patients with a longer survival also need to be identified correctly and the model fails to do so. It is the only score that takes time to development of SBM into account. This variable was associated with survival on multivariate analysis and could potentially be used to increase the accuracy of the predictive models.
Lastly, the recently published model by Bollen et al 7 was based on a retrospective analysis of 1043 patients treated with surgery and radiotherapy. Essentially, a hybrid of the models by Tomita et al 5 and Linden et al, 8 it has quite good results on both the short and long end of the survival spectrum. Even though the primary tumor classification is reasonably accurate, it still requires further specification of the malignancies in order to increase the discriminative ability.
CONCLUSION
This study provides an insight on how the available SBM models perform on a large dataset. The results suggest that the model by Bollen et al 7 performs best when identifying patients with a short and patients with a long expected survival. With the predicted survival outcome, appropriate choices for treatment can be made by patients and their treating physicians.
Key Points
Models estimating the survival of patients with spinal bone metastases can aid clinicians in selecting the most appropriate treatment. This study provides a direct comparison of the accuracy of six prognostic scores based on a large dataset. The model proposed by Bollen et al 7 offers the most accurate estimation of survival.
